ClinicalTrials.gg
TerminatedNCT00057343Updated Sep 12, 2006

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

A Phase 3 interventional study of Zevalin (ibritumomab tiuxetan) and Rituxan (rituximab) in Non-Hodgkin's Lymphoma, sponsored by Biogen. Terminated at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-09-12.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. ibritumomab tiuxetan · Lymphoma, Non-Hodgkin.

Enrollment
2nd of 17
400 · median 28
Started
2003
with 1 other
Phase 3
5 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
2 of 18
Biogen

Among the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2003, is one of 5 in phase 3, and was the 1st registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About ibritumomab tiuxetan

ibritumomab tiuxetan: first FDA approval 2002 (ZEVALIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin as a file.
02

Study summary

The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Summary of major inclusion and exclusion criteria. Other Safety criteria will need to be met.

Inclusion criteria

Inclusion Criteria:

  • confirmed, CD20+ follicular B-cell NHL within 12 months of Study Day 1 (without clinical evidence of transformation). NHL must require treatment as determined by an increase in overall tumor size. The presence of B symptoms, and/or the presence of masses which are causing ongoing clinical symptoms.
  • Bidimensionally meeting the minimum requirement of at least 1 lesion >/= 2.0 cm in a single dimension.
  • No lymphoma therapy for 3 weeks prior to Study Day 1.
  • Patients must be recovered from all toxicities associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy.
  • Signed IRB-approved .
  • Greater than 18 years of age.
  • Expected survival >/= 3 months.
  • of \</= 2.
  • Acceptable hematologic status, liver function, renal function, and pulmonary function.
  • Female patients who are not pregnant or lactating.
  • Men and women of who are following accepted methods.

Exclusion criteria

Exclusion Criteria:

  • Patients with impaired bone marrow reserve, which may be indicated by prior myeloablative therapy with bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue.
  • Prior radioimmunotherapy, including the Zevalin regimen.
  • Prior immunotherapy, including Rituxan therapy within 6 months of Study Day 1.
  • Rituxan- (no response to most recent Rituxan-containing regimen, or TTP was \< 6 months).
  • Presence of CNS lymphoma.
  • Patients with chronic lymphocytic leukemia (CLL).
  • Known history of or AIDS.
  • Serious nonmalignant disease or infection
  • Major surgery, other than diagnostic surgery, within 4 weeks of Study Day 1.
  • Patients who received product within 4 weeks of Study Day 1 or patients who may experience long-term toxicity from a previous investigational therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants
06

What researchers measure

Primary outcomes

  1. Event-free survival

Secondary outcomes

  1. overall response rate

  2. complete response rate

  3. unconfirmed complete response rate

  4. partial response rate

  5. duration of response

  6. time to progression

  7. time-to-next anticancer therapy

  8. quality of life

  9. overall survival

  10. safety profile

07

Study locations

67 sites
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Scottsdale, Arizona, United States
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Bakersfield, California, United States
  • Research Site
    Concord, California, United States
  • Research Site
    Duarte, California, United States
  • Research Site
    Loma Linda, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Mission Viejo, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Sacramento, California, United States
  • Biogen Idec Incorporated
    San Diego, California 92121, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Santa Barbara, California, United States
  • Research Site
    Vallejo, California, United States
  • Research Site
    Farmington, Connecticut, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Lakeland, Florida, United States
  • Research Site
    Boise, Idaho, United States
  • Research Site
    Coeur D'Alene, Idaho, United States
  • Research Site
    Aurora, Illinois, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Evanston, Illinois, United States
  • Research Site
    Harvey, Illinois, United States
  • Research Site
    Maywood, Illinois, United States
  • Research Site
    Urbana, Illinois, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Munster, Indiana, United States
  • Research Site
    Kansas City, Kansas, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Flint, Michigan, United States
  • Research Site
    Royal Oak, Michigan, United States
  • Research Site
    St. Joseph, Michigan, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    Jackson, Mississippi, United States
  • Research Site
    Tupelo, Mississippi, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Kansas City, Missouri, United States
  • Research Site
    St. Louis, Missouri, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Farmington, New Mexico, United States
  • Research Site
    Bronx, New York, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Manhasset, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Bismark, North Dakota, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Portland, Oregon, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Greenville, South Carolina, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Lubbock, Texas, United States
  • Research Site
    Temple, Texas, United States
  • Research Site
    Salt Lake City, Utah, United States
  • Research Site
    Bremerton, Washington, United States
  • Research Site
    Morgantown, West Virginia, United States
  • Research Site
    Wausau, Wisconsin, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 12, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00057343
Lead sponsor
Biogen
First posted
Apr 1, 2003
Start date
Mar 2003
Last update
Sep 12, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibritumomab tiuxetan · Rituximab

Start the discussion